HOME ·

TYK MEDICINES-B

TYK MEDICINES-B (02410.HK): H Share Subscription Agreement Lapses at Long-stop Date, 63.22 Million Shares
Tags：
NewTimeSpaceTYK MEDICINES-B02410.HK
2026-09-20
TYK MEDICINES-B (02410.HK): Chairman Wu Yusheng Buys Additional 635,000 H Shares for HKD 2.09 Million
Tags：
TYK MEDICINES-B02410.HKShare Increase
2026-09-11
TYK MEDICINES-B (02410.HK): Chairman Wu Yusheng Increases Shareholding with Planned Purchases of up to HKD 2 Million, Shares to Be Locked Up for Six Months
Tags：
TYK MEDICINES-B02410.HKShare Increase
2026-09-08
TYK MEDICINES-B (02410.HK): Dovatinib mesylate tablets (TY-9591) granted conditional approval as first-line treatment for EGFR-mutant NSCLC with CNS metastases
Tags：
TYK MEDICINES-B02410.HKClinical Progress
2026-08-27
TYK MEDICINES-B(02410.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at loss of CNY 24.9 million, loss narrowed by 77.81% YoY
Tags：
TYK MEDICINES-B02410.HKloss narrowed
2026-08-18
TYK MEDICINES-B (02410.HK): Initiates Litigation over Disputed TY-9591 Cooperation Agreement and Takes Legal Proceedings against Sichuan Huayu
Tags：
TYK MEDICINES-B02410.HKLitigation
2026-07-23